Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction
- 76 Downloads
The therapeutic effect of the α2-antagonist yohimbine in erectile dysfunction was studied in a double-blind placebo-controlled design. Thirty-one male patients underwent extensive clinical, urological, and psychiatric diagnosis and were dichotomically classified into an organic and a nonorganic subgroup. Following a 1-week placebo run-in period, patients were randomly assigned to a placebo or a verum group (yohimbine 15 mg daily) for a treatment period of 7 weeks. The Clinical Global Impression (CGI) scale was used as the primary efficacy parameter. Additionally, nocturnal penile tumescence and rigidity (NPTR) were measured. Global assessment of erectile function applying the CGI scale revealed, beyond a placebo effect in both organic and nonorganic patients, a therapeutic effect in the subgroup of nonorganic patients, with a significantly greater improvement in the yohimbine group compared to the placebo group. No superiority of yohimbine compared to placebo was found in the organic patients. These findings on the subjective level had no correlate in the NPTR recordings. The NPTR parameters were unchanged under yohimbine treatment in both the nonorganic and organic subgroup. No interrelation was found between subjective improvement and NPTR alterations. Polysomnographic control of the NPTR registrations ensured that the duration of REM sleep under treatment was not influenced.
Key Wordsyohimbine erectile dysfunction clinical global impression nocturnal penile tumescence and rigidity sleep EEG
Unable to display preview. Download preview PDF.
- American Psychiatric Association (1987).Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., rev., APA, Washington, DC.Google Scholar
- Guy, W. (1976).ECDEU Assessment Manual for Psychopharmacology, Revised, DHEW Publication (ADM), National Institute for Mental Health, Rockville, MD.Google Scholar
- Lancet. (1986). Yohimbine: Time for resurrection?Lancet 2: 1194–1195.Google Scholar
- Morales, A., Condra, M. S., Owen, J. E., Fenemore, J., and Surridge D. H. (1988). Oral and transcutaneous pharmacologic agents in the treatment of impotence.Urol. Clin. N. Am. 15: 87–93.Google Scholar
- Rechtschaffen, A., and Kales, A. (1968).A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects, Public Health Service, U.S. Government Printing Office, Washington, DC.Google Scholar
- Reynolds, C. F., Frank, E., Thase, M. E., Houck, P. R., Jennings, J. R., Howell, J. R., Lilienfeld, S. O., and Kupfer, D. J. (1988). Assessment of sexual function in depressed, impotent, and healthy men: factor analysis of a brief sexual function questionnaire for men.Psychiat. Res. 24: 231–250.CrossRefGoogle Scholar
- Riley, A. J., Goodman, R. E., Kellett, J. M., and Orr, R. (1989). Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy.Sex. Marital Ther. 4: 17–26.Google Scholar
- Sohn, M. H., Seeger, U., Sikora, R., and Jakse, G. (1993). Criteria for examiner-independent nocturnal penile tumescence and rigidity monitoring (NPTR): Correlations to invasive diagnostic methods.Int. J. Impotence Res. 5: 59–68.Google Scholar
- Steiger, A., Holsboer, F., and Benkert, O. (1987). Effects of brofaremine (CGP 11 305A), a short-acting, reversible, and selective inhibitor of MAO-A on sleep, nocturnal penile tumescence and nocturnal hormonal secretion in three healthy volunteers.Psychopharmacology 92: 110–114.PubMedCrossRefGoogle Scholar